On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients
| Autor: | George N. Dalekos, Christos Triantos, Konstantinos Mimidis, Christos Drakoulis, Ioannis Goulis, Evangelos Akriviadis, S. Karatapanis, George Germanidis, Maria Raptopoulou-Gigi, Georgios Bakalos, Elias Zintzaras, Melanie Deutsch, George V. Papatheodoridis |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male HBsAg medicine.medical_specialty Hepatitis B virus Alpha interferon medicine.disease_cause Gastroenterology Antiviral Agents Polyethylene Glycols Hepatitis B Chronic Internal medicine medicine Humans Hepatitis B e Antigens Prospective Studies Prospective cohort study Interferon alfa Hepatitis B Surface Antigens Hepatology business.industry virus diseases Interferon-alpha Odds ratio Middle Aged Prognosis digestive system diseases Recombinant Proteins Sustained response Immunology DNA Viral Female business Peginterferon alfa-2a medicine.drug |
| Zdroj: | Liver international : official journal of the International Association for the Study of the Liver. 35(5) |
| ISSN: | 1478-3231 |
| Popis: | Background & Aims We assessed predictors of response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a in routine clinical practice. Methods Ninety-five HBeAg-negative patients received peginterferonalfa-2a for 48 weeks and were followed-up for 48 weeks post-treatment. Serum HBsAg and HBV DNA levels were monitored during and after therapy with valid commercial assays. Sustained response (SR) was defined as HBV DNA 10% at 24 weeks is significantly associated with SR. The combination of the PARC rule and week 24 decline in HBsAg can identify almost two-thirds of patients who are unlikely to achieve SR. Clinicaltrials.gov identifier: NCT01283074. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text